Nationwide Children's Hospital, Department of Pathology and Laboratory Medicine, Columbus, OH. RATIONALE: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is a rare condition caused by mutations in FOXP3 resulting in defective regulatory T-cells (T regs ). We report two siblings with clinical presentations suggestive of IPEX with a novel variant in FOXP3. METHODS: A 5-year-old male (proband) was evaluated for diarrhea since infancy, intermittent fevers and arthralgias. Fecal calprotectin was markedly elevated and a colonic biopsy revealed findings of nonspecific inflammatory colitis, responsive to high-dose steroids. Family history was notable for type 1 diabetes mellitus in a 14 year-old brother who was subsequently diagnosed with nonspecific inflammatory colitis. CONCLUSIONS: Alterations in the frequency of cT FH cells subsets were observed in young CVID patients, whereas older CVID patients showed alterations in activated cT FH 1 and cT FR cells. These data suggest the importance of age in the study of these cells in the pathogenesis of CVID.
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An evaluation of patients initiated on Ig20Gly in a patient program Lisa M. Meckley, PhD; Shire, Cambridge, MA. RATIONALE: Currently, a patient product introduction program (HCUVP), which provides free-of-charge CuvitruÒ (Immune Globulin Subcutaneous (Human), 20% Solution, Ig20Gly) for the first 4 infusions to eligible patients with primary immunodeficiency (PIDD), is ongoing. The objective of this analysis was to describe the clinical characteristics and infusion parameters of patients initiated on Ig20Gly within the HCUVP. METHODS: Eligibility for HCUVP was: > _ 2 years of age with a primary ICD-10 diagnosis code verifying diagnosis of PIDD, and not using Ig20Gly at the time of program enrollment. This analysis includes data from patients enrolled in HCUVP, who received their first Ig20Gly infusion the between January 1-September 1, 2017. Infusions after October 31, 2017 were excluded. Descriptive statistics were calculated for demographic, clinical and prescribed infusion characteristics. RESULTS: In total, 934 patients were eligible for this analysis, who ranged in age between 2-89 (mean: 49.9). The most common PIDD diagnosis was common variable immunodeficiency (n5551, 59%). Among patients with available data on previous immunoglobulin (IG) therapy, 178 (37%) were treated with another subcutaneous IG product and 306 (63%) with intravenous IG. The mean prescribed IG dose per infusion was 14.9g (SD: 8.4), with 474 (51%) prescribed weekly and 411 (44%) biweekly. During the analysis period, 817 (87%) patients completed all four infusions.
CONCLUSIONS:
The results of this analysis provide more insights into the clinical characteristics of patients who have experienced Ig20Gly, and clinical use of Ig20Gly outside of a controlled clinical trial setting.
